Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

110 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, Wozniak AJ, Wolff AC. Smith TJ, et al. Among authors: wade jc, wade jl. J Clin Oncol. 2006 Jul 1;24(19):3187-205. doi: 10.1200/JCO.2006.06.4451. Epub 2006 May 8. J Clin Oncol. 2006. PMID: 16682719
Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma.
Moore DF Jr, Pazdur R, Abbruzzese JL, Ajani JA, Dubovsky DW, Wade JL 3rd, Belt RJ, Mangold C, Bready B, Winn RJ. Moore DF Jr, et al. Among authors: wade jl 3rd. Ann Oncol. 1994 Mar;5(3):286-7. doi: 10.1093/oxfordjournals.annonc.a058810. Ann Oncol. 1994. PMID: 8186177 Free article. Clinical Trial.
Randomized phase III study of 5-fluorouracil plus high dose folinic acid versus 5-fluorouracil plus folinic acid plus methyl-lomustine for patients with advanced colorectal cancer.
Jones DV Jr, Winn RJ, Brown BW, Levy LB, Pugh RP, Wade JL 3rd, Gross HM, Pendergrass KB, Levin B, Abbruzzese JL. Jones DV Jr, et al. Among authors: wade jl 3rd. Cancer. 1995 Nov 15;76(10):1709-14. doi: 10.1002/1097-0142(19951115)76:10<1709::aid-cncr2820761006>3.0.co;2-5. Cancer. 1995. PMID: 8625038 Clinical Trial.
2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel.
Ozer H, Armitage JO, Bennett CL, Crawford J, Demetri GD, Pizzo PA, Schiffer CA, Smith TJ, Somlo G, Wade JC, Wade JL 3rd, Winn RJ, Wozniak AJ, Somerfield MR; American Society of Clinical Oncology. Ozer H, et al. Among authors: wade jl 3rd, wade jc. J Clin Oncol. 2000 Oct 15;18(20):3558-85. doi: 10.1200/JCO.2000.18.20.3558. J Clin Oncol. 2000. PMID: 11032599 No abstract available.
American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer.
Loblaw DA, Mendelson DS, Talcott JA, Virgo KS, Somerfield MR, Ben-Josef E, Middleton R, Porterfield H, Sharp SA, Smith TJ, Taplin ME, Vogelzang NJ, Wade JL Jr, Bennett CL, Scher HI; American Society of Clinical Oncology. Loblaw DA, et al. Among authors: wade jl jr. J Clin Oncol. 2004 Jul 15;22(14):2927-41. doi: 10.1200/JCO.2004.04.579. Epub 2004 Jun 7. J Clin Oncol. 2004. PMID: 15184404
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline.
Loblaw DA, Virgo KS, Nam R, Somerfield MR, Ben-Josef E, Mendelson DS, Middleton R, Sharp SA, Smith TJ, Talcott J, Taplin M, Vogelzang NJ, Wade JL 3rd, Bennett CL, Scher HI; American Society of Clinical Oncology. Loblaw DA, et al. Among authors: wade jl 3rd. J Clin Oncol. 2007 Apr 20;25(12):1596-605. doi: 10.1200/JCO.2006.10.1949. Epub 2007 Apr 2. J Clin Oncol. 2007. PMID: 17404365 Review.
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.
Visvanathan K, Chlebowski RT, Hurley P, Col NF, Ropka M, Collyar D, Morrow M, Runowicz C, Pritchard KI, Hagerty K, Arun B, Garber J, Vogel VG, Wade JL, Brown P, Cuzick J, Kramer BS, Lippman SM; American Society of Clinical Oncology. Visvanathan K, et al. Among authors: wade jl. J Clin Oncol. 2009 Jul 1;27(19):3235-58. doi: 10.1200/JCO.2008.20.5179. Epub 2009 May 26. J Clin Oncol. 2009. PMID: 19470930 Free PMC article.
110 results